Basics Corbus Pharmaceuticals Holdings, Inc. Common Stock Corbus Pharmaceuticals Holdings Inc is a Phase 3 clinical-stage pharmaceutical company focused on the development and commercialization of novel therapeutics to treat rare, chronic, and serious inflammatory and fibrotic diseases. IPO Date: November 1, 2014 Sector: Healthcare Industry: Biotech Market Cap: $224.03M Activated in VL: True Average Daily Range Avg Daily Range: $0.32 | 3.89% Avg Daily Range (30 D): $0.60 | 4.34% Avg Daily Range (90 D): $0.38 | 3.43% Institutional Daily Volume Avg Daily Volume: 1.26M Avg Daily Volume (30 D): .25M Avg Daily Volume (90 D): .15M Trade Size Avg Trade Size (Sh.): 250 Avg Trade Size (Sh.) (30 D): 66 Avg Trade Size (Sh.) (90 D): 67 Institutional Trades Total Inst.Trades: 439 Avg Inst. Trade: $1.78M Avg Inst. Trade (30 D): $1.07M Avg Inst. Trade (90 D): $1.78M Avg Inst. Trade Volume: .04M Avg Inst. Trades (Per Day): 1 Market Closing Trades Avg Closing Trade: $2.07M Avg Closing Trade (30 D): $1.21M Avg Closing Trade (90 D): $3.01M Avg Closing Volume: 44.64K     News Oct 18, 2025 @ 7:00 AM Corbus Pharmaceuticals Presents CRB-701 Robust Cli... Source: Corbus Pharmaceuticals Jul 10, 2025 @ 5:00 PM Cannabinoid Agonist Clinical Trial Pipeline Appear... Source: Delveinsight May 22, 2025 @ 12:00 PM Corbus Pharmaceuticals to Present at the Jefferies... Source: N/A Jun 1, 2024 @ 2:00 PM SYS6002 (CRB-701) A Next-Generation Nectin-4 Targe... Source: Corbus Pharmaceuticals Holdings, Inc. May 23, 2024 @ 9:05 PM Updated Phase 1 Clinical Data for SYS-6002 (CRB-70... Source: Corbus Pharmaceuticals Holdings, Inc. Financials   TTM Q1 2025 Q4 2024 Basic EPS $-1.44 $-1.39 $-.76 Diluted EPS $-1.44 $-1.39 $-.76 Revenue $ 1.31M $ 1.68M $ 3.55M Gross Profit $ $ $ Net Income / Loss $ -17.66M $ -16.98M $ -9.53M Operating Income / Loss $ -19.15M $ -19.78M $ -12.61M Cost of Revenue $ $ $ Net Cash Flow $ M $ M $ -2.23M PE Ratio     Splits Feb 14, 2023:   1:30